Clinical Trials Logo

Filter by:
NCT ID: NCT05659056 Recruiting - Breast Cancer Clinical Trials

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Start date: November 29, 2022
Phase: Phase 2
Study type: Interventional

Breast cancer is kind of highly heterogeneous tumor. The patients with the same stage and with the same treatment regimen, their prognosis varies greatly, mainly due to the different phenotypes of breast cancer and different sensitivities to drug therapy. PMA50 and BluePrint classification divides breast cancer into other inherent subtypes: Luminal A, Luminal B, HER2-enriched (HER2-E) and Basal-like. Previous studies have shown that these patients with inherent subtype of HER2-enriched are more likely to obtain higher pCR after anti-HER2 therapy. And more study and meta analysis had demonstrated the higher pCR is closely related to EFS. The genetic and molecular typing of breast cancer is closely related to the prognosis of breast cancer, so it is imperative to seek a new treatment regimen for precision treatment and maximize the therapeutic benefit of HER2-enriched patients.

NCT ID: NCT05659043 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Glycation of apoA-I and Diabetic Atherogenesis

Start date: January 2017
Phase:
Study type: Observational

The goal of this study is to determine the relationship of apoprotein A-1 (apoA-I) glycation and development of diabetic atherosclerosis. ApoA-I is crucial for reverse cholesterol transport and anti-inflammation/anti-atherosclersis functions of HDL. However, apoA-I is easily subjected to non-enzymatic glycation modification in diabetic milleu. Our preliminary study has shown that apoA-I in HDL from type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) is significantly glycated, and site specific glycation of apoA-I impairs HDL function and is related to the development of atherosclerosis. To the best of our knowledge, less clinical information regarding apoA-I glycation and CAD has been reported. In this cross-sectional study, by consecutively enrolling diabetic patients with (two to three hundred) or without CAD (controls, six to eight hundred) in our hospital, we will isolate their serum HDL and perform a qualitative and quantitative proteomic analysis of apoA-I glycation. The relation of apoA-I glycation and HDL function and angiography-determined severity of CAD will be evaluated. Later, we will follow these diabetic patients to analyze the influence of apoA-I glycation on the outcome including plaque progression.

NCT ID: NCT05658718 Active, not recruiting - Refractive Surgery Clinical Trials

Factors Influencing Nocturnal Symptoms After Refractive Surgery.

Start date: November 1, 2021
Phase:
Study type: Observational

By comparing the parameters of the two groups of patients with glare at night after refractive surgery and those without glare at night, the influence of preoperative related parameters on postoperative glare was analyzed.

NCT ID: NCT05658705 Recruiting - Clinical trials for Primary Aldosteronism

Preoperative Supine Time for Adrenal Venous Sampling

PSTAVS
Start date: March 29, 2023
Phase: N/A
Study type: Interventional

This study aim to understand whether the length of preoperative supine time would affect the AVS outcome.

NCT ID: NCT05658692 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

PETARDS
Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to the ICU.

NCT ID: NCT05658484 Active, not recruiting - Multiple Sclerosis Clinical Trials

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Start date: June 9, 2023
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.

NCT ID: NCT05658081 Recruiting - Crohn Disease Clinical Trials

Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study

Start date: December 8, 2022
Phase: N/A
Study type: Interventional

The postoperative recurrence of Crohn's diseases (CD) remains high. Stapled anti-mesenteric functional end-to-end anastomosis was safe for CD patients. Its impact on the postoperative recurrence of CD was unknown. Whether it is superior than the conventional anastomosis (stapled antimesenteric isoperistaltic side-to-side anastomosis) needs explored. The trial aims to compare the different impacts of the two antimesenteric anastomosis configurations on the anastomotic recurrence following bowel resection.

NCT ID: NCT05658055 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of probiotics during vonoprazan-amoxicillin dual therapy on the gut microbiota in Helicobacter pylori eradication and to investigate whether the eradication rate of H.pylori will be improved when adding probiotics

NCT ID: NCT05658042 Recruiting - Infections Clinical Trials

Dose Optimization of Rivaroxaban Combined With Rifampicin

Start date: July 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about exposure levels of rivaroxaban at different doses in patients with prosthetic joint infection combined with the use of rifampicin. Participants will be collected blood samples to determine rivaroxaban plasma concentration. The main question it aims to answer is to predict the dose adjustment of rivaroxaban combined with the use of rifampin.

NCT ID: NCT05658003 Active, not recruiting - Clinical trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of [177Lu]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic castration-resistant prostate cancer patients, who were previously treated with another ARDT as last treatment and who have not been exposed to a taxane-containing regimen in castrate resistant prostate cancer (CRPC) or hormone-sensitive prostate cancer (HSPC) settings and who are considered appropriate for delaying taxane-based chemotherapy. The primary endpoint of rPFS will be assessed via blinded independent centralized review of radiographic images provided by the treating physician and as outlined in Prostate Cancer Working Group 3 (PCWG3) guidelines.